Boundless Bio remains a high-risk, pre-revenue biotechnology firm heavily reliant on the successful advancement of its ecDNA-targeted oncology pipeline.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 8, 2026 | -$0.60-4.0% vs -$0.58 | — vs — |
Q2 2026 Mar 9, 2026 | -$0.58-31.8% vs -$0.44 | — vs — |
Q4 2025 Nov 5, 2025 | -$0.62-17.0% vs -$0.53 | — vs — |
Q3 2025 Aug 5, 2025 | -$0.70+6.7% vs -$0.75 | — vs — |
Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch as Chief Corporate Affairs Officer - Lead program SERP-01 on track for Phase 2/3 initiation in late 2026 or early 2027 NEW YORK, Sept.
Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Zachary (“Zach”) Hornby as Chief Executive Officer.
Benchmark BOLD against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Boundless Bio, Inc. (BOLD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.46 | $55.29M | -0.86 | — | — | -70.89% | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — | |
| $4.37 | $177.42M | 8.17 | 55.25% | 58.87% | 6.24% | 23.45% | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — |
Boundless Bio, Inc. (BOLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Boundless Bio, Inc. (BOLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 23, 2026·SEC
Jun 17, 2026·SEC
May 8, 2026·SEC
Get notified when BOLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Boundless Bio, Inc. (BOLD) stock FAQ — growth, dividends, profitability & financials explained
No. Boundless Bio, Inc. (BOLD) reported a net loss of $64.0M over the trailing twelve months.
Boundless Bio, Inc. (BOLD) had a return on equity (ROE) of -70.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Boundless Bio, Inc. (BOLD) had negative free cash flow of $56.7M over the trailing twelve months.
